Nuveen Asset Management LLC Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Nuveen Asset Management LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,169,898 shares of the medical research company's stock after selling 216,591 shares during the period. Nuveen Asset Management LLC owned 0.54% of Edwards Lifesciences worth $234,668,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of EW. Vanguard Group Inc. increased its stake in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after buying an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC raised its position in Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after buying an additional 126,194 shares during the last quarter. Fisher Asset Management LLC raised its position in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new position in Edwards Lifesciences during the 4th quarter valued at $610,895,000. Institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Robert W. Baird upped their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Piper Sandler boosted their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $79.60.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the business's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the sale, the chief executive officer now directly owns 58,284 shares of the company's stock, valued at $4,366,054.44. The trade was a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,192 shares of company stock valued at $4,709,454 in the last ninety days. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.02 on Monday, hitting $78.02. 5,512,865 shares of the stock traded hands, compared to its average volume of 5,103,474. The firm has a market cap of $45.77 billion, a price-to-earnings ratio of 11.19, a PEG ratio of 4.82 and a beta of 1.12. The firm has a 50 day simple moving average of $72.08 and a two-hundred day simple moving average of $71.79. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the business earned $0.66 earnings per share. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.